Clinical Trial Update: Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for pelacarsen (TQJ230) evaluating Lp(a) lowering in Black/African American and Hispanic participants with elevated Lp(a) and esta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease

Drugs mentioned

• Pelacarsen (pelacarsen)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease | Phase 3 | Status: COMPLETED